Petruzzi M, De Benedittis M, Grassi R, Cassano N, Vena G, Serpico R. Oral lichen planus: a preliminary clinical study on treatment with tazarotene.
Oral Dis 2002;
8:291-5. [PMID:
12477060 DOI:
10.1034/j.1601-0825.2002.02833.x]
[Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE
The rationale for using tazarotene in oral lichen planus (OLP) is its regulatory action on the growth and differentiation of keratinocytes and on inflammation. This randomized, placebo-controlled study addresses evaluation of the effects of topic tazarotene in the treatment of OLP.
DESIGN
The degree of lesions before and after treatment scored by a 6-score scale in six cases treated with tazarotene was statistically compared with those of six controls treated with placebo.
SUBJECTS
Twelve patients with hyperkeratosic OLP were randomly allocated to treatment with tazarotene gel 0.1% b.i.d. or with placebo for eight consecutive weeks.
METHODS
The statistical comparison was executed by means of Wilcoxon analysis for paired data.
RESULTS
Patients treated with tazarotene presented a significant reduction of their lesions as compared with the control group. Among transitory side-effects, burning sensation and taste abnormalities were observed.
CONCLUSION
Topical tazarotene may be a valuable therapeutic tool in the treatment of hyperkeratotic OLP.
Collapse